NEW YORK, Aug. 28 – The SNP Consortium announced Tuesday that it had forged agreements with Motorola, Celera, Applied Biosystems, and Rutgers University that would enable it to build a SNP-based linkage map of the human genome by the end of the year.
In separate statements, the SNP Consortium said that Motorola had agreed to provide the genotyping services for the SNP map, while Celera and Applied Biosystems would provide data for creating the map. Celera will also use Applied Biosystem’s TaqMan reagents to validate some 2,000 SNPs from the consortium’s database.
The SNP Consortium, a non-profit group whose members include the Wellcome Trust as well as leading pharmaceutical companies and research centers, also said that Rutgers University’s Laboratory of Computational Genetics had been selected to analyze the results.
The Consortium said it would make its linkage map available for free to researchers around the world.
Financial terms of the deals were not disclosed, and the consortium did not say how much it would invest in building the map.
Participants in the deals said that they believed such a map would accelerate the development of new medical treatments and diagnostics.
"The SNP Consortium believes a genome-wide, SNP-based linkage map will add considerable value to the database of SNPs that the Consortium has created to date," Arthur Holden, CEO of the SNP Consortium, said in a statement.
"We are pleased to be working with the SNP Consortium to create a genome-wide SNP-based linkage map as it is an important step toward better understanding of human genetic variations and should allow for more rapid design of improved diagnostics and therapeutics," Craig Venter, Celera's president and chief scientific officer, said in a statement.